Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are
diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low …

Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …

Abstract c-Met is a receptor tyrosine kinase belonging to the MET (MNNG HOS transforming
gene) family, and is expressed on the surfaces of various cells. Hepatocyte growth factor …

Attempts to develop MET-targeted therapies have historically focused on MET-expressing
cancers, with limited success. Thus, MET expression in the absence of a genomic marker of …

Predictive biomarkers are the mainstay of precision medicine. This review summarizes the
advancements in tissue-based diagnostic biomarkers for gastric cancer, which is considered …

The MET oncogene encodes an unconventional receptor tyrosine kinase with pleiotropic
functions: it initiates and sustains neoplastic transformation when genetically altered …

Molecular targeted therapy for cancer has been a research hotspot for decades. AXL is a
member of the TAM family with the high-affinity ligand growth arrest-specific protein 6 …

MET encodes a receptor tyrosine kinase c-MET for hepatocyte growth factor (HGF). The
specific combination of c-MET and HGF activates downstream signaling pathways to trigger …

Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …

As one of the most abundant immune cell populations in the tumor microenvironment (TME),
tumor‐associated macrophages (TAMs) play important roles in multiple solid malignancies …